PROTEIN CELL 润色咨询

Protein & Cell

出版年份:暂无数据 年文章数:348 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2020-06-01 ms8714998894105664

    审稿速度:1.0
    经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?
    我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。
    pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!
    投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection....

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-09-26 ms3000001738384174

    老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2022-04-05 12334177m32(暂无昵称)

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:无

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2022-02-13 ms3000001264860737

    就这杂志的德性还想和elife,pnas或者cell report比,简直做梦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-12-28 衣谷

    上传文章有什么要求?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-12-27 乌云背后的幸福线

    如何判断两种药物之间是协同作用还是相加作用?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-09-19 wfkevinhan

    破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2020-06-29 qsqsqsqs12

    10.164,跻身一流刊物了

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2020-08-17 ms3000000505063897

    最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),
    和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports
    (scr)作对照。

    惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research
    highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两
    三篇,有时候仅仅一篇,其余七八篇都是综述。

    cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一
    篇综述,研究性文章中仅有2到3篇reports,其余都是articles。
    同样scr每期刊文15篇左右
    ,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。



    从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研
    究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,
    其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell
    reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=861262, encodeId=4b2d8612621c, content=审稿速度:1.0<br>经验分享:我觉得pc是非常好的杂志啊,为何前面的留言要喷他?<br> 我们文章投过去3天送审,审稿10天,审稿意见回来后2天就给了decision,效率特别高。3个审稿人,a和b提的意见普遍比较靠谱,让补的实验也算合理。我们当时就一个审稿人c比较tricky,让我们补了这个又补那个。。。。后来第二轮的时候编辑自己也写了一段意见,认为一篇文章讲好一个故事即可,没有让我们按审稿人c的意见继续补实验。<br> pc这个杂志article很少,大部分是letter。我们的文章第一次投的article,审下来被拒。后来补了一年实验又投,审下来还是达不到articel的要求,编辑问要不要改成letter发表。我们研究了一下近3年pc的letter,觉得水平也不错。2年硕士时光,能发一篇letter也算知足了,希望以后努力能发一篇article!<br> 投稿前,我曾经把网上对pc的一些评论转发给老板看,老板说了一句经典的话:网上的戾气,往往源自rejection.... , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Jun 01 11:32:04 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055111, encodeId=ae821055111c4, content=老板随口说让试试10分以上的,结果秒拒,模板拒稿,意料之中。估计很难中!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23305505580, createdName=ms3000001738384174, createdTime=Sun Sep 26 20:55:30 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208849, encodeId=93171208849cc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32b92391219, createdName=12334177m32(暂无昵称), createdTime=Tue Apr 05 21:54:58 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193123, encodeId=9b871193123b7, content=就这杂志的德性还想和elife,pnas或者cell report比,简直做梦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Sun Feb 13 22:34:43 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105165, encodeId=ef8511051651a, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105166, encodeId=de3a11051665d, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052966, encodeId=3578105296680, content=破四维破的是国外的SCI,其实完全可以把国产SCI全搞成中科院1区,不发国产SCI,中不了国自然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Sep 19 09:28:24 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800297, encodeId=243080029e38, content=10.164,跻身一流刊物了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:40:38 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809550, encodeId=bb0280955027, content=最近我深入研究了一下2本国产神刊,即所谓影响银子达20多两的Cell research(cr),<br>和10两的protein cell(pc),我把cell旗下的cell reports(crs)与stem cell reports<br>(scr)作对照。<br><br>惊人的发现:cr每期刊不到15篇,超过一半就是特邀的综述和评论性(Research<br>highlights)文章,而pc则更夸张,每期不到10篇文章,研究性文章大多数时候都是两<br>三篇,有时候仅仅一篇,其余七八篇都是综述。<br><br>cell开放性子刊crs每期刊文18篇左右,青一色研究性论文,没有一<br>篇综述,研究性文章中仅有2到3篇reports,其余都是articles。<br>同样scr每期刊文15篇左右<br>,仅仅有2篇综述,其余都是研究性文章,reports仅仅2篇,其余都是articles。<br><br><br><br>从上面文章类型我们可以看出,cr至今还是靠综述和评论性文章拉分,抛掉这些,cr研<br>究论文的实际档次甚至不如crs,也就是说此期刊的实际银子在10以下。pc抛去综述,<br>其研究论文的实际档次也就scientific reports,实际银子不到5两。而cell<br>reports 与stem cell reports真心佩服,几乎都是研究论文,货真价实。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=841, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0315411393, createdName=ms3000000505063897, createdTime=Mon Aug 17 04:22:05 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947101, encodeId=833994e1014a, content=大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Wed Mar 10 13:31:30 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-10 张晓梅-Xiaomei Zhang

    大家注意,有一些单位在评职称和基金时,已明确规定,letter不当成正规文章,会影响评审结果。 虽然目前是个别单位,但像是有蔓延的趋势。国内发letter太多了,早晚会出问题的,劝大家如果文章有内容,尽量还是先投经典期刊的article类型,不要投letter to editor,尤其是你还想在科研的路上走

    0

共61条页码: 1/7页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分